MLYS (Mineralys Therapeutics) Marketable Securities: $533.28 Mil (As of Mar. 2026)


MLYS Mineralys Therapeutics Inc MLYS
37 GF Score
Price $28.38
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Marketable Securities?

Mineralys Therapeutics MLYS -2.00% 37 Marketable Securities is $533.28 Mil as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Mineralys Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $533.28 Mil.

Mineralys Therapeutics's annual Marketable Securities declined from Dec. 2023 ($187.26 Mil) to Dec. 2024 ($84.10 Mil) but then increased from Dec. 2024 ($84.10 Mil) to Dec. 2025 ($483.71 Mil).

Mineralys Therapeutics  (NAS:MLYS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Mineralys Therapeutics Marketable Securities Related Terms

Mineralys Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Marketable Securities Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 22.41 187.26 84.10 483.71

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.02 223.13 376.03 483.71 533.28
MLYS
37GF Score
Mineralys Therapeutics Inc MLYS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $533.28 Mil mean?
Mineralys Therapeutics (MLYS) has a Marketable Securities of $533.28 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Mineralys Therapeutics and its competitors.
Is Mineralys Therapeutics' Marketable Securities too high?
Mineralys Therapeutics' current Marketable Securities is $533.28 Mil. Overall, Mineralys Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Marketable Securities compare to VCEL and NRIX?
Mineralys Therapeutics' Marketable Securities of $533.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Marketable Securities is $533.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Marketable Securities of $533.28 Mil. The current Marketable Securities is $533.28 Mil. Mineralys Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Marketable Securities is $533.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
37GF Score

Get the complete analysis for MLYS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.38
Price